Strong prospects in wound care
Tissue Regenix’s (L:TRX) investment case is built on dCELL, a patented decellularised tissue scaffold, whose regenerative properties are applied in wound care, orthopaedics and cardiac implants. We see wound care as the main driver for TRX’s growth and our sum-of-the-parts valuation of £346m. Our forecasts and valuation are unchanged, but updated for a stronger US dollar.
Wound care market set for sustainable growth
The $8.5bn global advanced wound care market is set to sustain 4-5% CAGR driven by an ageing population and rising incidence of ailments such as diabetes and obesity. We expect innovation adoption to remain brisk, notably in the US, with a low double-digit growth rate expected in the $0.5bn dermal substitute market. With the top three players controlling half the market, industry consolidation looks set to continue, focusing on building scale and securing new technologies.
TRX’s technology well positioned in wound care
TRX is a new entrant with a novel dermal substitute, DermaPure HD, launched in 2014. In a competitive market, we believe it is well placed due to the proven efficacy of DermaPure to treat both chronic and acute wounds, but also from a regulatory and health economic perspective. TRX’s technology benefits from being clean, easy to handle and effective at promoting healing.
To read the entire report Please click on the pdf File Below